Literature DB >> 20463014

Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.

Gin-Ah Song1, Hyun-Jung Kim, Kyung-Mi Woo, Jeong-Hwa Baek, Gwan-Shik Kim, Jin-Young Choi, Hyun-Mo Ryoo.   

Abstract

Fibrodysplasia ossificans progressiva (FOP), a rare genetic and catastrophic disorder characterized by progressive heterotopic ossification, is caused by a point mutation, c.617G>A; p.R206H, in the activin A receptor type 1 (ACVR1) gene, one of the bone morphogenetic protein type I receptors (BMPR-Is). Although altered BMP signaling has been suggested to explain the pathogenesis, the molecular consequences of this mutation are still elusive. Here we studied the impact of ACVR1 R206H mutation on BMP signaling and its downstream signaling cascades in murine myogenic C2C12 cells and HEK 293 cells. We found that ACVR1 was the most abundant of the BMPR-Is expressed in mesenchymal cells but its contribution to osteogenic BMP signal transduction was minor. The R206H mutant caused weak activation of the BMP signaling pathway, unlike the Q207D mutant, a strong and constitutively active form. The R206H mutant showed a decreased binding affinity for FKBP1A/FKBP12, a known safeguard molecule against the leakage of transforming growth factor (TGF)-beta or BMP signaling. The decreased binding affinity of FKBP1A to the mutant R206H ACVR1 resulted in leaky activation of the BMP signal, and moreover, it decreased steady-state R206H ACVR1 protein levels. Interestingly, while WT ACVR1 and FKBP1A were broadly distributed in plasma membrane and cytoplasm without BMP-2 stimulation and then localized in plasma membrane on BMP-2 stimulation, R206H ACVR1 and FKBP1A were mainly distributed in plasma membrane regardless of BMP-2 stimulation. The impaired binding to FKBP1A and an altered subcellular distribution by R206H ACVR1 mutation may result in mild activation of osteogenic BMP-signaling in extraskeletal sites such as muscle, which eventually lead to delayed and progressive ectopic bone formation in FOP patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463014      PMCID: PMC2903413          DOI: 10.1074/jbc.M109.094557

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

Review 1.  Traffic jam: a compendium of human diseases that affect intracellular transport processes.

Authors:  M Aridor; L A Hannan
Journal:  Traffic       Date:  2000-11       Impact factor: 6.215

Review 2.  Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders.

Authors:  N Gregersen; P Bross; M M Jørgensen; T J Corydon; B S Andresen
Journal:  J Inherit Metab Dis       Date:  2000-07       Impact factor: 4.982

3.  Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling.

Authors:  Anke Hartung; Keren Bitton-Worms; Maya Mouler Rechtman; Valeska Wenzel; Jan H Boergermann; Sylke Hassel; Yoav I Henis; Petra Knaus
Journal:  Mol Cell Biol       Date:  2006-08-21       Impact factor: 4.272

Review 4.  Regulation of osteoblast differentiation by transcription factors.

Authors:  Toshihisa Komori
Journal:  J Cell Biochem       Date:  2006-12-01       Impact factor: 4.429

5.  Hypoxic adipocytes pattern early heterotopic bone formation.

Authors:  Elizabeth Olmsted-Davis; Francis H Gannon; Mustafa Ozen; Michael M Ittmann; Zbigniew Gugala; John A Hipp; Kevin M Moran; Christine M Fouletier-Dilling; Shannon Schumara-Martin; Ronald W Lindsey; Michael H Heggeness; Malcolm K Brenner; Alan R Davis
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

6.  BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells.

Authors:  Karen Lavery; Pamela Swain; Dean Falb; Moulay Hicham Alaoui-Ismaili
Journal:  J Biol Chem       Date:  2008-04-24       Impact factor: 5.157

7.  FKBP12 is a negative regulator of transforming growth factor-beta receptor internalization.

Authors:  D Yao; J J Doré; E B Leof
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

8.  Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12.

Authors:  K S Lee; H J Kim; Q L Li; X Z Chi; C Ueta; T Komori; J M Wozney; E G Kim; J Y Choi; H M Ryoo; S C Bae
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

9.  Early diagnosis of fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Meiqi Xu; David L Glaser; Felicity Collins; Michael Connor; Joseph Kitterman; David Sillence; Elaine Zackai; Vardit Ravitsky; Michael Zasloff; Arupa Ganguly; Eileen M Shore
Journal:  Pediatrics       Date:  2008-05       Impact factor: 7.124

10.  Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP).

Authors:  Paul C Billings; Jennifer L Fiori; Jennifer L Bentwood; Michael P O'Connell; Xiangyang Jiao; Burton Nussbaum; Robert J Caron; Eileen M Shore; Frederick S Kaplan
Journal:  J Bone Miner Res       Date:  2008-03       Impact factor: 6.741

View more
  55 in total

1.  Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or--how does one tissue become another?

Authors:  Eileen M Shore
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012 Jan-Feb       Impact factor: 5.814

2.  Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.

Authors:  Tim N Beck; Vladislav A Korobeynikov; Alexander E Kudinov; Rachel Georgopoulos; Nehal R Solanki; Magda Andrews-Hoke; Timothy M Kistner; David Pépin; Patricia K Donahoe; Emmanuelle Nicolas; Margret B Einarson; Yan Zhou; Yanis Boumber; David A Proia; Ilya G Serebriiskii; Erica A Golemis
Journal:  Cell Rep       Date:  2016-07-07       Impact factor: 9.423

Review 3.  Stem cells and heterotopic ossification: Lessons from animal models.

Authors:  John B Lees-Shepard; David J Goldhamer
Journal:  Bone       Date:  2018-01-31       Impact factor: 4.398

4.  Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.

Authors:  Bettina E Mucha; Megumi Hashiguchi; Joseph Zinski; Eileen M Shore; Mary C Mullins
Journal:  Bone       Date:  2018-01-04       Impact factor: 4.398

5.  CNS demyelination in fibrodysplasia ossificans progressiva.

Authors:  Lixin Kan; Joseph A Kitterman; Daniele Procissi; Salin Chakkalakal; Chian-Yu Peng; Tammy L McGuire; Robert E Goldsby; Robert J Pignolo; Eileen M Shore; Frederick S Kaplan; John A Kessler
Journal:  J Neurol       Date:  2012-06-27       Impact factor: 4.849

6.  ACVR1 mutations and the genomic landscape of pediatric diffuse glioma.

Authors:  Gelareh Zadeh; Kenneth Aldape
Journal:  Nat Genet       Date:  2014-05       Impact factor: 38.330

Review 7.  Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Curr Osteoporos Rep       Date:  2011-06       Impact factor: 5.096

Review 8.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

9.  The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes.

Authors:  Silvia Colucci; Alessia Pagani; Mariateresa Pettinato; Irene Artuso; Antonella Nai; Clara Camaschella; Laura Silvestri
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

Review 10.  Tissue engineered bone mimetics to study bone disorders ex vivo: Role of bioinspired materials.

Authors:  Yuru Vernon Shih; Shyni Varghese
Journal:  Biomaterials       Date:  2018-06-06       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.